These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3962800)

  • 21. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships.
    Gupta SK; Sathyan G; Lindemulder EA; Ho PL; Sheiner LB; Aarons L
    Clin Pharmacol Ther; 1999 Jun; 65(6):672-84. PubMed ID: 10391673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combination of oxybutynin chloride (Ditropan) with intermittent catheterization in the treatment of neurogenic bladder in childhood: results on continence].
    De Castro R; Casolari E; Ricci S
    Pediatr Med Chir; 1984; 6(6):795-803. PubMed ID: 6545593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxybutinin and the prevention of urinary incontinence in spina bifida.
    Hehir M; Fitzpatrick JM
    Eur Urol; 1985; 11(4):254-6. PubMed ID: 3899664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse back pain and urological symptoms: recognizing tethered cord syndrome early.
    Shaya MR; Willis BK; Nanda A
    J La State Med Soc; 2005; 157(1):39-41. PubMed ID: 15887667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bladder instability and abdominal pain in children].
    García Nieto V; Castro Díaz D; Uroz Tristán J; Ravina Pisaca M; Hernández Yanes JR
    An Esp Pediatr; 1990 Feb; 32(2):159-62. PubMed ID: 2346247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urologic manifestation of the tethered spinal cord.
    Kaplan WE; McLone DG; Richards I
    Z Kinderchir; 1987 Dec; 42 Suppl 1():27-31. PubMed ID: 3433971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional daytime incontinence: pharmacological treatment.
    Hjälmås K; Passerini-Glazel G; Chiozza ML
    Scand J Urol Nephrol Suppl; 1992; 141():108-14; discussion 115-6. PubMed ID: 1609246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children].
    Aubert D; Cencig P; Royer M
    Ann Pediatr (Paris); 1986 Sep; 33(7):629-34. PubMed ID: 3777773
    [No Abstract]   [Full Text] [Related]  

  • 31. Improving treatment of urinary incontinence.
    Resnick NM
    JAMA; 1998 Dec; 280(23):2034-5. PubMed ID: 9863856
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence.
    Hussain RM; Hartigan-Go K; Thomas SH; Ford GA
    Br J Clin Pharmacol; 1996 Jan; 41(1):73-5. PubMed ID: 8824696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
    Chapple CR; Abrams P
    Eur Urol; 2005 Jul; 48(1):102-9. PubMed ID: 15936869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hyperhidrosis with oxybutynin.
    Schollhammer M; Misery L
    Arch Dermatol; 2007 Apr; 143(4):544-5. PubMed ID: 17438194
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 37. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 38. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of coexistent stress and urge urinary incontinence.
    Karram MM; Bhatia NN
    Obstet Gynecol; 1989 Jan; 73(1):4-7. PubMed ID: 2909042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxybutynin and urinary incontinence.
    Castleden CM; Battcock TM; Duffin HM
    Age Ageing; 1990 Jan; 19(1):72-3. PubMed ID: 2316427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.